BACKGROUND: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. METHODS: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. RESULTS: Among 7847 biological treatment episodes, 63% were for biological-free patients and 37% for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biological-free patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p<0.0001). After multivariable adjustment controlling for biological-free/switcher status and other infection-related factors and compared with infliximab, users of abatacept (HR 0.68, 95% CI 0.48 to 0.96), adalimumab (HR 0.52, 0.39 to 0.71), etanercept (HR 0.64, 0.49 to 0.84) and rituximab (HR 0.81, 0.55 to 1.20) had lower rates of hospitalised infection. Patient risk factors contributed more to the risk of infection than did the risk associated with specific biological therapies. CONCLUSION: The rate of hospitalised infections among RA patients was highest for infliximab. Most of the variability in patients' risk of infection was driven by factors other than biological agent exposure.
BACKGROUND: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. METHODS: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. RESULTS: Among 7847 biological treatment episodes, 63% were for biological-free patients and 37% for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biological-free patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p<0.0001). After multivariable adjustment controlling for biological-free/switcher status and other infection-related factors and compared with infliximab, users of abatacept (HR 0.68, 95% CI 0.48 to 0.96), adalimumab (HR 0.52, 0.39 to 0.71), etanercept (HR 0.64, 0.49 to 0.84) and rituximab (HR 0.81, 0.55 to 1.20) had lower rates of hospitalised infection. Patient risk factors contributed more to the risk of infection than did the risk associated with specific biological therapies. CONCLUSION: The rate of hospitalised infections among RApatients was highest for infliximab. Most of the variability in patients' risk of infection was driven by factors other than biological agent exposure.
Authors: Carine Salliot; Axel Finckh; Wanruchada Katchamart; Yan Lu; Ye Sun; Claire Bombardier; Edward Keystone Journal: Ann Rheum Dis Date: 2010-11-19 Impact factor: 19.103
Authors: F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette Journal: Arthritis Rheum Date: 2009-07
Authors: Gert J D Bergman; Marc C Hochberg; Maarten Boers; Neil Wintfeld; Adrian Kielhorn; Jeroen P Jansen Journal: Semin Arthritis Rheum Date: 2010-03-11 Impact factor: 5.532
Authors: Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink Journal: Semin Arthritis Rheum Date: 2010-08 Impact factor: 5.532
Authors: D Salmon-Ceron; F Tubach; O Lortholary; O Chosidow; S Bretagne; N Nicolas; E Cuillerier; B Fautrel; C Michelet; J Morel; X Puéchal; D Wendling; M Lemann; P Ravaud; X Mariette Journal: Ann Rheum Dis Date: 2010-12-21 Impact factor: 19.103
Authors: Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell Journal: CMAJ Date: 2009-11-02 Impact factor: 8.262
Authors: Suzanne M Cadarette; Joshua J Gagne; Daniel H Solomon; Jeffrey N Katz; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2010-01 Impact factor: 2.890
Authors: W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons Journal: Ann Rheum Dis Date: 2009-10-22 Impact factor: 19.103
Authors: Gladys Ting; Sebastian Schneeweiss; Richard Scranton; Jeffrey N Katz; Michael E Weinblatt; Melissa Young; Jerry Avorn; Daniel H Solomon Journal: Arthritis Res Ther Date: 2008-08-21 Impact factor: 5.156
Authors: Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Jessica M Franklin; Daniel H Solomon; Karen H Costenbader; Seoyoung C Kim Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Huifeng Yun; Fenglong Xie; Elizabeth Delzell; Lang Chen; Emily B Levitan; James D Lewis; Kenneth G Saag; Timothy Beukelman; Kevin Winthrop; John W Baddley; Jeffrey R Curtis Journal: Ann Rheum Dis Date: 2014-03-07 Impact factor: 19.103